FindTrial
Sign In

To evaluate the primary skin irritation potential and safety profile of Skinovate Gentle Cleanser, Rice Water Serum, Face Wash, Moisturizer, Sunscreen, Night Serum, and Night Brightening Cream using a 24-hour occlusive patch test on healthy human volunteers.

To assess the primary skin irritation potential and safety of Skinovate Gentle Cleanser, Rice Water Serum, Face Wash, Moisturizer, Sunscreen, Night Serum, and Night Brightening Cream by a 24-hour occlusive patch test in healthy human volunteers - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098568
Enrollment
24
Registered
2025-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Skinovate Laser Cosmetic Surgery Center
Lead Sponsor
Skinovate Laser Cosmetic Surgery Center
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1 Males and females aged 18 65 years 2 Healthy by medical history and investigator exam 3 Intact facial skin areas for patch application no cuts active dermatitis infections 4 Fitzpatrick skin types I VI accepted 5 Women of childbearing potential must use contraception and have negative pregnancy test 6 Willing to provide informed consent and comply with study procedures

Exclusion criteria

Exclusion criteria: 1 Pregnant or lactating women 2 Known hypersensitivity to ingredients in IPs 3 History of atopic dermatitis chronic eczema psoriasis affecting test area 4 Active acneiform or follicular infection at application site 5 Use of systemic retinoids within 6 months or topical retinoids steroids at site within 4 weeks 6 Immunosuppressive therapy within 4 weeks 7 Photosensitivity dermatographism severe allergy history 8 Participation in another interventional study or investigational product within 30 days 9 Recent vaccination or planned vaccination during study 10 Any condition interfering with safety or data interpretation

Design outcomes

Primary

MeasureTime frame
To assess the primary skin irritation potential of the above Skinovate skin products in healthy volunteers after a single occluded 24hour application 2 h measured by Draize scale scores at 24 and 48-hours post-applicationTimepoint: three months—

Secondary

MeasureTime frame
To evaluate overall safety and tolerability based on incidence frequency and severity of adverse events AEs SAEs To document subject-reported sensations at the test site itching burning stinging tightness Timepoint: three months—

Countries

India

Contacts

Public ContactDr Sonal Shendkar

Skinovate Laser Cosmetic Surgery Center,

drsonal.skinovate@gmail.com09743849130

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026